SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending due to exceptionally high short interest fueling intense short squeeze speculation, amplified by recent global regulatory approvals for its Anktiva cancer treatment. The community is rallying behind Dr. Patrick Soon-Shiong's vision for a potential chemo-free cancer solution, actively discussing the drug's expanding market potential and the increasing pressure on short sellers.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending following its Q4 earnings, which revealed a wider-than-expected loss despite revenue beating estimates, alongside news of a 12% workforce reduction and concerns over future share dilution. The community is heavily discussing the company's high cash burn, its challenging path to profitability, and the lack of a permanent CEO, while some optimists point to revenue growth and institutional investor interest as potential positives.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical (DRTS) is surging following its Japan PMDA marketing approval for Alpha DaRT and encouraging clinical updates for a second Glioblastoma (GBM) patient. The community is highly bullish, anticipating a significant breakout as institutional interest grows and the company transitions to global commercialization of its physics-based 'universal killer' cancer treatment.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

WEEDCOIN CRYPTO is trending as its community anticipates momentum around the upcoming '4/20' period, actively promoting it as a 'culture coin' on Solana for the global cannabis community. Discussions highlight its long-term vision and the broader potential of cannabis, citing recent research and policy developments, despite some skepticism about volatility.

DHT Holdings, Inc. engages in the operation of a fleet of crude oil tankers. It operates through its integrated management companies in Monaco, Singapore, and Oslo, Norway. The company was founded in 2005 and is headquartered in Hamilton, Bermuda.

DHT Holdings Inc

DHT Holdings is trending as a pure-play VLCC tanker company capitalizing on global tariffs and geopolitical tensions that are extending oil shipping routes and tightening vessel supply, leading to skyrocketing charter rates. The community is highly bullish, viewing it as a "dividend monster" with a 100% net income payout policy, expecting significant future payouts.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is actively discussed due to a potential short squeeze, fueled by Tether's increasing ownership and substantial investment commitments for advertising and cloud services, alongside its strategic acquisition of Northern Data for AI infrastructure and the rollout of its 'Rumble Shorts' feature.

HP Inc. is an information technology company, which engages in the provision of personal computing and other access devices, imaging and printing products, and related technologies, solutions, and services. It operates through the following segments: Personal Systems, Printing, and Corporate Investments. The Personal Systems segment offers commercial and consumer desktop and notebook personal computers, workstations, thin clients, commercial tablets and mobility devices, retail point-of-sale systems, displays and other related accessories, software, support, and services for the commercial and consumer markets. The Printing segment provides consumer and commercial printer hardware, supplies, solutions and services, and scanning devices. The Corporate Investments segment includes HP Labs and certain business incubation projects. The company was founded by William R. Hewlett and David Packard in 1939 and is headquartered in Palo Alto, CA.

HP Inc

HPQ is actively trending as its CEO's departure to PayPal compounds investor concern over recent weak guidance and rising memory costs, yet a strong contingent of the community sees deep value in its dividend yield and long-term AI PC potential at current depressed levels.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending as community discussion explodes following Donald Trump's State of the Union address, with supporters hailing his speech while critics accuse him of delivering a 'clown show' full of lies, alongside renewed chatter around tariffs and ongoing Epstein claims.

First Solar, Inc. is a solar technology company, which engages in the provision of solar modules. It is involved in the design, manufacture, and sale of cadmium tellurid (CdTe) solar modules, which convert sunlight into electricity. The company was founded by Michael J. Ahearn in 1999 and is headquartered in Tempe, AZ.

First Solar Inc

First Solar is seeing a significant pullback following 2026 sales guidance that underwhelmed analyst expectations, driven by concerns over tariffs and policy uncertainty. While many are expressing disappointment and shorting the stock, a segment of the community views the dip as a buying opportunity, citing FSLR's robust U.S. manufacturing and the burgeoning energy demand from AI data centers as long-term tailwinds.

Workday, Inc. engages in the provision of development of enterprise cloud applications for finance and human resources. It delivers financial management, human capital management and analytics applications designed for companies, educational institutions, and government agencies. The company was founded by David A. Duffield and Aneel Bhusri in 2005 and is headquartered in Pleasanton, CA.

Workday Inc - Ordinary Shares - Class A

Workday Inc

Workday is trending after its recent Q4 earnings, where a beat on current results was overshadowed by a weaker FY27 subscription revenue outlook, intensifying concerns about AI's disruptive impact on the broader software sector. The community is actively debating if the stock's significant decline is an overreaction, especially given Workday's confirmation that leading AI companies are among its customers.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>TeraWulf is expected to report fourth-quarter revenue of $44.1 million, according to data from fiscal.ai. The company in the same quarter last year reported a revenue of $35 million.&nbsp;</li><li>A user on Stocktwits predicted that the stock will cross $30 post its earnings because of WULF’s growth in energy and data centers.&nbsp;</li><li>TeraWulf has been pivoting aggressively from Bitcoin mining toward high-performance computing and AI data center hosting.&nbsp;</li></ul>Shares of TeraWulf rallied 10% on Tuesday as investors eagerly await its quarterly earnings that are expected to come this week.&nbsp;At the time of writing, stock was up 13% at $17.74.&nbsp;<h2 class="st-heading-2">What Is Retail Thinking?</h2>Retail sentiment around WULF trended in ‘neutral’ territory amid ‘low’ message volume.&nbsp;One bullish user said that if bitcoin is believed to be at $150,000 levels, then WULF stock can reach $60 by the end of 2026.&nbsp;<stembedurl>https://stocktwits.com/zingman/message/645741240</stembedurl>Another bullish user said that they wished to have 100 times more WULF shares than they currently own.&nbsp;<stembedurl>https://stocktwits.com/AllMarkets/message/645735377</stembedurl>Yet&nbsp;another user predicted that the stock will cross $30 post its earnings because of WULF’s growth in energy and data centers.&nbsp;<stembedurl>https://stocktwits.com/jam324/message/645735138</stembedurl><h2 class="st-heading-2">Q4 Earnings Preview</h2>TeraWulf is expected to report fourth-quarter revenue of $44.1 million, according to data from fiscal.ai. The company in the same quarter last year reported a revenue of $35 million.&nbsp;The company is also expected to post a higher loss of $0.14 per share in the fourth quarter compared to a loss per share of $0.08 in the same quarter last year.&nbsp;<h2 class="st-heading-2">Company’s Move To AI/HPC</h2>TeraWulf has been&nbsp; pivoting aggressively from Bitcoin mining toward high-performance computing (HPC) and AI data center hosting. Earlier in the month, it announced that it is expanding its digital and power infrastructure portfolio.The company said it is expanding its portfolio through the acquisition of two strategically located brownfield infrastructure sites in Hawesville, Kentucky and Charles County, Maryland.TeraWulf’s infrastructure portfolio now totals approximately 2.8 GW across five sites, including 642.5 MW of contracted capacity and 2.2 GW of owned pipeline capacity.This expanded development pipeline supports its growth strategy targeting 250 to 500 MW of new contracted capacity annually, aligned with customer demand, power availability, and regional grid conditions.WULF stock has rallied more than 300%&nbsp;over the past 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

 In this photo illustration, the TeraWulf (Tera Wulf) logo is seen displayed on a smartphone screen.

Terawulf Stock Is Up 10% But Retail Still Sees More Than 250% Upside: Here’s Why

Analysts expect the company to post higher fourth quarter revenue than the year-ago quarter, as per data from fiscal.ai. 

Equity

Analysts expect the company to post higher fourth quarter revenue than the year-ago quarter, as per data from fiscal.ai. 


Should Schwab U.S. Small-Cap ETF (SCHA) Be on Your Investing Radar?

<ul class="summary-bullets"><li>Wealth-management stocks slid on Tuesday after tech platform Altruist introduced an AI-powered tax planning tool.</li><li>Wurster said the selloff left him “disappointed and surprised” because he believes that AI would strengthen advisers’ capabilities.</li><li>Schwab is well-positioned to benefit from AI due to its scale and extensive data, Wurster added.</li></ul>Charles Schwab (SCHW) CEO Rick Wurster pushed back against growing concerns that artificial intelligence could disrupt the wealth management industry, arguing instead that the technology will enhance adviser productivity.Wurster emphasized that AI should be viewed as a supportive tool rather than a replacement for human expertise, according to a Bloomberg interview on Wednesday. “With the power of AI, not only are we reaching those clients we have a relationship with, we are able to help a whole new group of clients,” Wurst said.His comments came after a selloff that dragged down shares of several wealth-management firms following the launch of Altruist’s AI-powered tax planning tool on Tuesday.<a href="https://stocktwits.com/symbol/SCHW">SCHW stock</a> was down 3% in morning trade after closing over 7% lower in the previous session.<h2 class="st-heading-2">Altruist’s AI Tool Leads To Selloff</h2>Wealth-management stocks slid on Tuesday after tech platform Altruist introduced an AI-powered tax planning tool within its Hazel platform, raising concerns about pressure on traditional advisory services. Shares of Raymond James Financial fell over 8%, while Stifel Financial declined around 4% on Tuesday.The tool analyzes client financial data to create personalized tax strategies, aiming to improve outcomes and efficiency. Altruist added that strict zero data-retention agreements ensure customer information is not stored or used to train AI models.<h2 class="st-heading-2">Wurster Says He Is Disappointed And Surprised By Recent Selloff</h2>Wurster said the decline in the brokerage’s shares left him “disappointed and surprised” because he believes that artificial intelligence would strengthen advisers’ capabilities rather than replace them.“The market is missing that we are a natural winner in the AI space because of all of the advantages we have — because of our size, our scale, our data,” he said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment shifted to ‘bullish’ from ‘bearish’ a day earlier, amid ‘extremely high’ message volumes.<img src="https://news.stocktwits-cdn.com/SCHW_jpg_af0628c78b.webp" alt="SCHW.jpg">However, some users expressed concerns about the company’s future amid the “AI onslaught”.<stembedurl>https://stocktwits.com/Free43ver/message/644650446</stembedurl><stembedurl>https://stocktwits.com/Mahaperrotta/message/644618898</stembedurl>SCHW stock has shed over 3% so far in 2026.was up 1.6% in pre-market trading after closing over 7% lower in the previous session.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/khc-stock-slumps-weak-q4-results-pauses-separation/cZb6X4CR4qY">Kraft Heinz Pauses Separation Plan Amid Weak Q4 Print – KHC Stock Slumps 7% Pre-Market</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the Charles Schwab company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Charles Schwab CEO Reportedly Explains Why AI Won’t Disrupt Wealth Management Industry: ‘We Are Able To Help A Whole New Group Of Clients’

CEO Rick Wurster said that AI should be viewed as a supportive tool rather than a replacement for human expertise, according to an interview with Bloomberg on Wednesday.

Will the Ongoing Market Rally Continue in 2026? ETFs in Focus

S&P 500 momentum and retail inflows set the stage for a potential 2026 rally, with ETFs offering ways to ride the bullish trend.

More Fed Rate Cuts in 2026? ETFs to Play the Opportunities

Softer inflation and dovish signals point to more 2026 rate cuts. These ETFs can help investors ride potential gains.

ETFs to Benefit From Rate Cut Bets and Upbeat Forecasts

ETFs to watch as Wall Street turns upbeat, with bullish forecasts putting the S&P 500 on track for 8,000 by 2026.

<ul class="summary-bullets"><li>Neumora said that NMRA-215 demonstrated weight loss of up to 19% as a monotherapy and 26% in combination with semaglutide.</li><li>The company now plans to initiate an early-stage clinical study for the experimental drug in the first quarter of 2026. &nbsp;</li></ul>Neumora Therapeutics, Inc. (NMRA) on Monday announced positive data from preclinical studies for its experimental weight-loss therapy NMRA-215.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/27/3174401/0/en/Neumora-Therapeutics-Announces-Class-Leading-Weight-Loss-Demonstrated-with-NMRA-215-in-Preclinical-Diet-Induced-Obesity-Model.html">said</a> that NMRA-215 demonstrated weight loss of up to 19% as a monotherapy and 26% in combination with Semaglutide in mice with diet-induced obesity. Semaglutide is the active ingredient in Novo Nordisk’s (NVO) popular weight-loss drug Wegovy.<h2 class="st-heading-2">Plans Ahead</h2>NMRA-215 is an oral NLRP3 inhibitor in development for the treatment of obesity. It blocks the activity of the NLRP3 inflammasome, a protein complex involved in the immune response to inflammation. NLRP3-mediated neuroinflammation in the hypothalamus is linked to obesity, Neumora noted.The company now plans to initiate an early-stage clinical study for the experimental drug in the first quarter of 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Shares of the company jumped about 22% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NMRA">NMRA stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<blockquote>“These data demonstrate NMRA-215 drives meaningful weight loss as a monotherapy in mice, including incretin-like induction, additive weight loss in the combination setting with semaglutide, as well as the potential to enable incretin-sparing dosing regimens.” – Paul Berns, CEO, Neumora Therapeutics</blockquote>Separately, Neumora on Monday also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/27/3174424/0/en/Neumora-Therapeutics-Announces-Initiation-of-Phase-1-Clinical-Study-of-M4-Positive-Allosteric-Modulator-NMRA-898.html">announced</a> the initiation of an early-stage study of its NMRA-898 aimed at evaluating safety, tolerability, and human pharmacokinetic data of the compound for potential use in the treatment of schizophrenia and other neuropsychiatric disorders.&nbsp;NMRA stock is down by 75% this year and by about 78% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/eth-outperforms-btc-as-retail-sentiment-improves-ahead-of-fed-rate-decision/cLG030ZR3Mh">Ethereum Outperforms Bitcoin As Retail Sentiment Improves Ahead Of Fed Rate Decision, Trump-Xi Meeting This Week</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Neumora Therapeutics’ Experimental Drug Demonstrates Weight Loss in Preclinical Studies

Neumora said that NMRA-215 demonstrated weight loss of up to 19% as a monotherapy and 26% in combination with Semaglutide.

Shares of Alto Neuroscience (ANRO) soared 54% on Friday afternoon after the company announced that the U.S. Food and Drug Administration granted Fast Track designation to ALTO-101 for the treatment of cognitive impairment associated with schizophrenia.Cognitive impairment is a core and disabling feature of Schizophrenia, a serious, disabling mental illness affecting thought, perception, and behavior. According to Alto, there are currently no approved treatments for cognitive impairment associated with schizophrenia.FDA’s Fast Track designation is designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need. A company, whose drug has a Fast Track designation, may be eligible for more frequent meetings with the FDA to discuss the drug’s development plan, as well as for accelerated approval and priority review, subject to the fulfillment of relevant criteria.ALTO-101 is an inhibitor of the PDE4 enzyme that plays a key role in the brain by breaking down a molecule fundamental to learning and memory. By inhibiting the enzyme, the drug seeks to increase the levels of the molecule believed to improve cognitive function.Alto CEO Amit Etkin <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.altoneuroscience.com/news/news-details/2025/Alto-Neuroscience-Receives-FDA-Fast-Track-Designation-for-ALTO-101-for-the-Treatment-of-Cognitive-Impairment-Associated-with-Schizophrenia/default.aspx">termed</a> the designation a significant milestone. “Our Phase 1 data, which demonstrated significant and clinically relevant effects of ALTO-101 on both EEG measures and cognitive performance in healthy subjects, provides strong validation for its mechanism,” he added.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ANRO">ANRO stock</a> rose from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:579/59;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_03_at_12_01_14_PM_png_f2a3fffa4a.webp" alt="ANRO's Sentiment Meter and Message Volume as of 12 p.m. ET on Oct. 03, 2025 | Source: Stocktwits" width="579" height="59"><figcaption>ANRO's Sentiment Meter and Message Volume as of 12 p.m. ET on Oct. 03, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user highlighted the company’s strong pipeline. Alto is seeking to develop treatments for mental health conditions, including bipolar depression, major depressive disorder, treatment-resistant depression (TRD), and schizophrenia.<stembedurl>https://stocktwits.com/Ccperk/message/630959482</stembedurl>Another user believes the FDA's Fast Track designation is the icing on the cake.<stembedurl>https://stocktwits.com/Ccperk/message/630949029</stembedurl>ANRO stock is up by 61% this year but down by 33% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rivian-reportedly-eyes-door-redesign-to-alleviate-safety-concerns-report/chCuVXzR3QQ">Rivian Reportedly Eyes Door Redesign To Alleviate Safety Concerns: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Alto Neuroscience logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Alto Neuroscience Stock Soars After FDA Grants Fast Track Designation To Schizophrenia Drug

FDA’s Fast Track designation is designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need.

ETFs to Ride the Small-Cap Comeback Wave 

Rate cut hopes and investor rotation beyond tech are fueling renewed momentum in small-cap stocks, with the Russell 2000 surging in August.

Schwab Strategic Trust - Schwab U.S. Small-Cap ETF

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

Ahead of earnings, sentiment is split between blowout AI growth and concerns around macro pressure, positioning, and post-ER volatility. How do you see it playing out?

SCHA
Schwab Strategic Trust - Schwab U.S. Small-Cap ETF

Feed

News

Sentiment

Fundamentals

Info

Latest SCHA News

SCHASchwab Strategic Trust - Schwab U.S. Small-Cap ETF